Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients Full Text
Annals of Oncology, 05/10/2012
Kluger N et al. – Permanent and severe alopecia is a newly reported complication of the fluorouracil/epirubicin/cyclophosphamide (FEC) 100–docetaxel breast cancer regimen.Methods
- Women treated for breast cancer by a sequential adjuvant FEC and docetaxel regimen who developed permanent alopecia diagnosed between 2007 and 2011 were identified from the Department of Dermatology and the Department of Medical Oncology.
- Data were collected regarding demographics, type of cancer, delay of onset after chemotherapy, Dermatology Life Quality Index (DLQI), clinical description of the lesions, scalp biopsies, laboratory explorations investigating steroid hormonal, iron, zinc and thyroid status, therapy and outcome.
- Twenty white Caucasian females were included. Hair loss presented with a moderate or intense androgenetic-like pattern of scalp alopecia.
- Biopsy specimen examinations were normal or displayed the androgenetic-like pattern.
- Laboratory explorations ruled out iron or zinc deficiency and thyroid disorders and confirmed hormonal menopause without hyperandrogenism.
- The overall mean DLQI score reflected the distressing psychological consequences in the patients' lives.
- No spontaneous regrowth of the scalp hair was noted.
- Treatment including vitamins, minoxidil, psoralen and ultraviolet A therapy and spironolactone proved to be ineffective.